(Q43361070)

20 November 2017

title

Can schistosomiasis really be consigned to history without a vaccine? (English)

1 reference

20 November 2017

0 references

4

1 reference

20 November 2017

David J Diemert

2

0 references

author name string

Jeffrey M Bethony

series ordinal

1

1 reference

20 November 2017

Sergio Costa Oliveira

series ordinal

3

1 reference

20 November 2017

language of work or name

English

0 references

publication date

7 May 2008

1 reference

20 November 2017

1 reference

20 November 2017

volume

26

1 reference

20 November 2017

issue

27-28

1 reference

20 November 2017

page(s)

3373-3376

1 reference

The renaissance in global health

20 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Waterborne infectious diseases--could they be consigned to history?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

The neglected tropical diseases: the ancient afflictions of stigma and poverty and the prospects for their control and elimination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

A blueprint for success: integration of neglected tropical disease control programmes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Water contact observations in Kenyan communities endemic for schistosomiasis: methodology and patterns of behaviour

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Seeking the ghost of worms past

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Puberty and Age-related Changes in Susceptibility to Schistosome Infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Patterns in parasite epidemiology: the peak shift

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Immunity after treatment of human schistosomiasis mansoni. II. Identification of resistant individuals, and analysis of their immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Immunity after treatment of human schistosomiasis mansoni. I. Study design, pretreatment observations and the results of treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Human immunity to Schistosoma mansoni: observations on mechanisms, and implications for control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Longitudinal studies on human schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Resistance to reinfection after treatment of urinary schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Praziquantel treatment of individuals exposed to Schistosoma haematobium enhances serological recognition of defined parasite antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Human immunity to Schistosomes: some questions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Human resistance to Schistosoma infections: age or experience?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Praziquantel: mechanisms of anti-schistosomal activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Active immunization of mice with Schistosoma mansoni worm membrane antigens enhances efficacy of praziquantel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Elevated proliferation and interleukin-4 release from CD4+ cells after chemotherapy in human Schistosoma haematobium infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Common features of T cell reactivity in persistent helminth infections: lymphatic filariasis and schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Recognition of Schistosoma mansoni cathepsins B and L by human IgG1 and IgG4 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

The impact of chemotherapy on morbidity due to schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Continued ultrasonic follow-up of children infected with Schistosoma haematobium after treatment with praziquantel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Evolution of Schistosoma haematobium-related pathology over 24 months after treatment with praziquantel among school children in southeastern Tanzania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Resistance of Schistosoma mansoni to praziquantel: is there a problem?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Schistosomiasis control: keep taking the tablets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Schistosomes: the road from host-parasite interactions to vaccines in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Current status of vaccines for schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Nucleic acid vaccination with Schistosoma mansoni antioxidant enzyme cytosolic superoxide dismutase and the structural protein filamin confers protection against the adult worm stage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Investigation of recombinant Schistosoma japonicum paramyosin fragments for immunogenicity and vaccine efficacy in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

A Schistosoma mansoni fatty acid-binding protein, Sm14, is the potential basis of a dual-purpose anti-helminth vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Vaccine efficacy of recombinant cathepsin D aspartic protease from Schistosoma japonicum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Immunization with plasmid DNA encoding the integral membrane protein, Sm23, elicits a protective immune response against schistosome infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Proteins exposed at the adult schistosome surface revealed by biotinylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

'Oming in on schistosomes: prospects and limitations for post-genomics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Human antibody responses of patients living in endemic areas for schistosomiasis to the tegumental protein Sm29 identified through genomic studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

7 January 2021

The antipoverty vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Neglected tropical diseases, neglected data sources, and neglected issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.04.045

10.1016/J.VACCINE.2008.04.045

7 January 2021

Identifiers

DOI

1 reference

20 November 2017

1 reference